Under the first agreement with the Accelerator and Bioincubator Lab (ABI-LAB), Cytovia will move into a laboratory space at the ABI-LAB facility in Natick, MA. The company has started recruiting research and development and process development personnel to its team. Cytovia will maintain its existing cell therapy operation with the New York Stem Cell Foundation and antibody good manufacturing practice (GMP) manufacturing with STC Biologics.

The Natick labs will conduct activities for NK cell biology, gene editing, antibody and CAR development, and NK cell pilot manufacturing. The NK cell technology will be directly transferred to larger-scale operations in Puerto Rico.

Under the second agreement, Cytovia has signed a long-term joint manufacturing and operations agreement with BioSciencesCorp in Puerto Rico. This will integrate Cytovia's manufacturing processes within an existing 95,000-sq-ft current GMP (cGMP) facility that includes more than 40,000 sq ft of clean-room and biomanufacturing space. The facility is located in Aguadilla, Puerto Rico. Cytovia will recruit manufacturing personnel beginning in summer 2021.

Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and...

Cytovia licenses CAR NK tech to NCI
Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its...